C4 Launches, Makes Deal With Roche | Chemical & Engineering News
Volume 94 Issue 2 | p. 17 | Concentrates
Issue Date: January 11, 2016

C4 Launches, Makes Deal With Roche

Department: Business
Keywords: drug discovery, ubiquitin/proteasome, venture capital

C4 Therapeutics has launched from James E. Bradner’s lab at Dana-Farber Cancer Institute with $73 million in financing. The firm is developing Degronimids, small-molecule binders that target disease-causing proteins and facilitate their clearance from cells through the natural ubiquitin-proteasome system. The molecules offer a promising approach for previously undruggable proteins, it says. At the same time, C4 will work with Roche to develop Degronimids against unspecified targets. The deal could be worth more than $750 million.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment